A large number of tumour-infiltrating Tregs are considered to contribute to resistance to anti-PD1 therapy and are associated with worse overall survival (Jenkins et al., 2018; Upadhaya et al., 2021). The gene discussed is PDCD1; the disease is neoplasm.